Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations

• Status: Completed
• Trial end date: 2018-11-25
• Target enrollment: 0
• Participant gender: All

Summary

The study will investigate the ability of a new PET tracer, 18F-AV-1451, to detect depositions of a protein, called tau, in the brains of people with a mutation in the tau gene that causes deposition of the protein, and in people without the mutation. Up to three 18F-AV-1451 scans will be performed (one per year) on control subjects without MAPT mutations, presymptomatic mutation carriers, and symptomatic mutation carriers.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Columbia University
• Collaborator: National Institute of Neurological Disorders and Stroke (NINDS)

Criteria

Inclusion Criteria:

• Members of families with established MAPT mutations, who either have the capacity to consent to participate in the protocol, or else have designated a surrogate/proxy to consent to participate in this study

Exclusion Criteria:

• Unwillingness to participate

• Usage of medication which significantly prolongs QT interval

• Pregnancy or plans for pregnancy within 90 days after participating in study